1,081
Views
4
CrossRef citations to date
0
Altmetric
Laboratory Studies

Experimental comparison of protective characteristics of enalapril and trimetazidine in diabetic nephropathy

, , , , , , , & show all
Pages 1283-1290 | Received 18 Dec 2013, Accepted 17 May 2014, Published online: 10 Jul 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

F. Fırat, M. Özgül, E. Türköz Uluer & S. Inan. (2019) Effects of caffeic acid phenethyl ester (CAPE) on angiogenesis, apoptosis and oxidatıve stress ın various cancer cell lines. Biotechnic & Histochemistry 94:7, pages 491-497.
Read now

Articles from other publishers (3)

Kirti Gupta, Sneha Pandey, Newly Bagang, Kamalpreet Mehra & Gaaminepreet Singh. (2021) Trimetazidine an emerging paradigm in renal therapeutics: Preclinical and clinical insights. European Journal of Pharmacology 913, pages 174624.
Crossref
Qin Zhang, Ming Yang, Ying Xiao, Yachun Han, Shikun Yang & Lin Sun. (2021) Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy. Current Medicinal Chemistry 28:5, pages 1003-1024.
Crossref
Yong Yang, Yong Wang, Zuowen He, Yunchang Liu, Chen Chen, Yan Wang, Dao Wen Wang & Hong Wang. (2020) Trimetazidine Inhibits Renal Tubular Epithelial Cells to Mesenchymal Transition in Diabetic Rats via Upregulation of Sirt1. Frontiers in Pharmacology 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.